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Key Points Summary 1 
• The Transient Receptor Potential Ankyrin 1 (TRPA1) ion channel is expressed 2 
in nociceptive neurons and its activation causes ongoing pain and inflammation. 3 
TRPA1 is thought to play an important role in inflammation in the airways. 4 
• TRPA1 is sensitised by repeated stimulation with chemical agonists in a 5 
calcium-free environment. This sensitisation is very long-lasting following 6 
agonist removal. 7 
• We show that agonist-induced sensitisation is independent of the agonist’s 8 
binding site and is also independent of ion channel trafficking or of other typical 9 
signalling pathways. 10 
• We find that sensitisation is intrinsic to the TRPA1 protein and is accompanied 11 
by a slowly developing shift in the voltage dependence of TRPA1 towards more 12 
negative membrane potentials. 13 
• Agonist-induced sensitisation may provide an explanation for sensitisation 14 
following long-term exposure to harmful irritants and pollutants, particularly in 15 
the airways.   16 
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Abstract 1 
The TRPA1 ion channel is expressed in nociceptive (pain-sensitive) neurons and 2 
responds to a wide variety of chemical irritants, such as acrolein in smoke or 3 
isothiocyanates in mustard. Here we show that in the absence of extracellular calcium 4 
the current passing through TRPA1 gradually increases (sensitises) during prolonged 5 
application of agonists. Activation by an agonist is essential, because activation of 6 
TRPA1 by membrane depolarisation did not cause sensitisation. Sensitisation is 7 
independent of the site of action of the agonist, because covalent and non-covalent 8 
agonists were equally effective, and is long-lasting following agonist removal. Mutating 9 
N-terminal cysteines, the target of covalent agonists, did not affect sensitisation by the 10 
non-covalent agonist carvacrol, which activates by binding to a different site. 11 
Sensitisation is unaffected by agents blocking ion channel trafficking or by block of 12 
signalling pathways involving ATP, protein kinase A or the formation of lipid rafts, and 13 
does not require ion flux through the channel. Examination of the voltage dependence 14 
of TRPA1 activation shows that sensitisation is accompanied by a slowly developing 15 
shift in the voltage dependence of TRPA1 towards more negative membrane 16 
potentials, and is therefore intrinsic to the TRPA1 channel. Sensitisation may play a 17 
role in exacerbating the pain caused by prolonged activation of TRPA1. 18 
 19 
Abbreviations 20 
TRPA1, Transient Receptor Potential Ankyrin 1; AITC, Allyl isothiocyanate; DRG, 21 
dorsal root ganglion; HEK293t, Human embryonic kidney 293t cell line; MβCD, Methyl-22 
β-cyclodextrin; PKA, Protein kinase A; WTA, Wheat germ agglutinin; WT, wildtype   23 
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Introduction 1 
The Transient Receptor Potential Ankyrin 1 (TRPA1) channel is unique in its ability to 2 
respond to a wide range of irritant agonists, many found in the everyday environment, 3 
hence the term “irritant receptor”. The channel is expressed in neurons of 4 
somatosensory ganglia (Story et al., 2003; Jordt et al., 2004; Nagata et al., 2005; 5 
Anand et al., 2008) and its agonists trigger pain and inflammation. Electrophilic 6 
agonists, such as allyl-isothiocyanate (AITC, mustard oil), cinnamaldehyde, 7 
formaldehyde and acrolein activate TRPA1 by forming covalent bonds with three 8 
intracellular N-terminal cysteine residues (Story et al., 2003; Bandell et al., 2004; 9 
Bautista et al., 2006; Hinman et al., 2006; McNamara et al., 2007; Macpherson et al., 10 
2007). Non-electrophilic agonists, such as menthol, carvacrol (contained in oregano) 11 
and nicotine activate TRPA1 without causing  modification of cysteines (Karashima et 12 
al., 2007; Lee et al., 2008; Talavera et al., 2009). TRPA1 is also activated by a range of 13 
endogenous ligands (Andersson et al., 2008; Eberhardt et al., 2012), protons (de la 14 
Roche et al., 2013), and possibly by noxious cold temperatures, although this remains 15 
controversial (Story et al., 2003; Jordt et al., 2004; Bautista et al., 2006; Zurborg et al., 16 
2007; Karashima et al., 2009; Gentry et al., 2010). Intracellular and extracellular 17 
calcium activate TRPA1 and potentiate its response to several agonists; the activation 18 
is followed by long lasting inactivation of the channel (Jordt et al., 2004; Zurborg et al., 19 
2007; Doerner et al., 2007a; Wang et al., 2008b).  20 
Behavioural studies in rodents as well as genome wide association studies in humans 21 
demonstrate a role for TRPA1 in nociception, making the channel a promising target for 22 
the development of novel analgesics (Obata et al., 2005; Bautista et al., 2006; Kwan et 23 
al., 2006; Caceres et al., 2009; Kremeyer et al., 2010; Bell et al., 2014). As many of its 24 
agonists can potentially be inhaled, TRPA1 has become an important target for the 25 
treatment of inflammatory airway diseases.  26 
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Inflammation releases a range of inflammatory mediators which cause a lowering of the 1 
activation threshold of peripheral nociceptive nerve fibers. TRPA1 is sensitised by 2 
bradykinin or by activators of proteinase-activated receptor 2 (PAR2) via activation of 3 
intracellular pathways involving protein kinase A (PKA) and phospholipase C (Dai et 4 
al., 2007; Wang et al., 2008a; Schmidt et al., 2009). TRPA1 can also be sensitised by 5 
prolonged application of agonists in calcium-free conditions (Raisinghani et al., 2011). 6 
Such agonist-induced sensitisation could be important for the body’s response during 7 
prolonged exposure to irritants and allergens. Elucidating the mechanism behind 8 
agonist-induced sensitisation is important in understanding both the function of TRPA1 9 
and its role in pathologies such as lung inflammation.  10 
Here, we investigate agonist-induced sensitisation of human TRPA1 and we show that 11 
this process is independent of the principal cell signalling pathways and also does not 12 
involve enhanced channel trafficking to the cell membrane. We find that agonist-13 
induced sensitisation is accompanied by a slow shift of the voltage dependence of 14 
channel activation towards more negative membrane potentials, leading to a slowly 15 
developing and long-lasting gain in channel activation. The shift is rapidly reversed on 16 
removal of agonist but rapidly reappears on re-presentation of the agonist. We suggest 17 
that activation by an agonist causes sensitisation through a long-lasting and slowly-18 
reversible change in the structure of TRPA1.  19 
Materials and Methods 20 
Ethical Approval 21 
Studies involving animals were approved by the Home Office (UK) and by the Animal 22 
Welfare and Ethical Review Body, University of Cambridge. 23 
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Cell culture and transfection 1 
Cell culture was performed as previously described (Fischer et al., 2013) with the 2 
following changes. Dorsal root ganglia (DRGs) were collected from C57BL/6 mice of 3 
either sex aged 6–16 weeks, sacrificed by cervical dislocation. Harvested ganglia were 4 
transferred into calcium- and magnesium-free Hank’s Balanced Salt Solution and 5 
treated with 2 mg/ml papain (Sigma-Aldrich, UK), followed by 2.5 mg/ml collagenase 6 
type IV (Invitrogen) for 30 min at 30°C. HEK293t cells were transfected using 7 
Metafectene (Biontex Laboratories GmbH, Martinsried/Planegg, Germany) according to 8 
the manufacturer’s instructions. Electrophysiological recordings were performed on the 9 
day following the transfection. All experiments were performed at room temperature.  10 
Plasmids, cloning and mutagenesis 11 
Human TRPA1-V5 was obtained from Dr Xuming Zhang (University of Aberdeen, 12 
Scotland). Human TRPA1 cDNA (hTRPA1) was subcloned into a pcDNA5/FRT-13 
mTRPA1-IRES-YFP vector, using HindIII and XbaI. The vector was a kind gift from Dr 14 
Ardem Patapoutian (Scripps Research Institute, La Jolla, CA). The hTRPA1 cDNA 15 
containing three cysteine-to-serine mutations (C621S, C641S, C665S) was obtained 16 
from Dr Carla Nau (University Medical Center Schleswig-Holstein, Lübeck, Germany) 17 
and was cloned into the same pcDNA5/FRT-IRES-YFP vector. All constructs were 18 
confirmed by sequencing. 19 
Calcium imaging 20 
Ratiometric calcium imaging was performed using the calcium-sensitive dye fura-2. 21 
Cells were loaded with fura-2 AM (5 μM) in the presence of 0.02% pluronic F-127 (both 22 
Invitrogen) for 30 min at 37°C in serum- and antibiotic-free DMEM. Medium was 23 
changed to HEPES-buffered extracellular solution (in mM: 140 NaCl, 4 KCl, 1.8 CaCl2, 24 
1 MgCl2, 10 HEPES, and 5 glucose, adjusted to pH 7.4) and neurons were left to 25 
  7 
equilibrate at room temperature in the dark for 5 min and then mounted on a Nikon 1 
Eclipse Ti-E inverted microscope with a 10× Plan Fluor objective. Cells were 2 
continuously superfused with extracellular solution or test solutions through a common 3 
outlet. Cells were illuminated with a monochromator alternating between 340  10 and 4 
380  10 nm (OptoScan; Cairn Research Ltd, Faversham, UK), controlled by WinFluor 5 
3.2 software (Dr John Dempster, University of Strathclyde, Glasgow, UK). Ratiometric 6 
calcium imaging as described above was also used to identify DRG neurons 7 
expressing TRPA1 for patch clamp recordings from their responsiveness to AITC. 8 
Neurons were exposed to AITC (50 µM) for 40 s and responders identified. A selected 9 
neuron was then patched for whole-cell voltage clamp recordings. Immediately after 10 
establishing the whole-cell configuration perfusion was switched to calcium-free 11 
extracellular solution for 2 min before beginning the voltage clamp recording. Note that 12 
at least 5 min passed between the end of the AITC application and the start of the 13 
voltage clamp recording.  14 
Patch clamp electrophysiology 15 
Whole-cell voltage clamp was performed on transfected HEK293t cells or on DRG 16 
neurons selected by calcium imaging (see above). Membrane currents were acquired 17 
with an Axopatch 200B amplifier (Molecular Devices, Wokingham, UK), low-pass 18 
filtered at 2 kHz and sampled at 10 kHz. The pClamp 9 or 10 software (Molecular 19 
Devices, Wokingham, UK) was used for acquisition and offline analysis. Series 20 
resistance was compensated up to 75%. Glass electrodes (GB150F-8P; Science 21 
Products GmbH, Hofheim, Germany) were fabricated (P-97; Sutter Instruments, 22 
Novato, USA) and heat polished on a microforge (MF-830; Narishige International Ltd, 23 
Tokyo, Japan) to a final resistance of 2–5 MΩ. Cells were continuously superfused with 24 
extracellular solution or test solutions through a common outlet. Solution changes were 25 
controlled by an automated system using pinch-valves designed by Dr. V. Vellani (CV 26 
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Scientific, Inc). Solution changes at the cell position were complete (10% – 90% 1 
concentration change) within 100 ms, which was significantly more rapid than the time 2 
course of TRPA1 current activation in response to agonist (see below). All recordings 3 
were performed in calcium-free HEPES-buffered extracellular solution (see above). In 4 
experiments using ATP-free intracellular solution the extracellular solution contained no 5 
glucose. In experiments designed to evoke maximal TRPA1 currents using 5 mM 6 
carvacrol, external sodium was reduced to 10 mM to reduce voltage-clamp artefacts 7 
caused by large current flows. NaCl was substituted by choline-chloride (130 mM), and 8 
titrated with CsOH. The internal solution contained the following (in mM): 140 KCl, 1.6 9 
MgCl2, 2.5 MgATP, 0.5 NaGTP, 2 EGTA, and 10 HEPES, adjusted to pH 7.3. In ATP-10 
free experiments, MgATP and NaGTP were substituted with MgCl2 and NaCl2, 11 
respectively. All experiments were performed at room temperature and at a holding 12 
potential of −60 mV.  13 
To investigate voltage dependence, a 500 ms voltage ramp protocol from −100 mV to 14 
+100 mV was applied every 5 s. Voltage dependence was also tested at given time 15 
points using 80 ms voltage pulses ranging from −140 mV to +220 mV in 30 mV 16 
increments from a holding potential of –60 mV, followed by a step to +60 mV for 80 ms 17 
for tail current analysis, and a final step back to −60 mV for 160 ms (see Figure 6 B). 18 
TRPA1 currents were corrected for leak conductance obtained from a hyperpolarising 19 
pulse to –140 mV in the absence of agonist. Half-maximal voltage gating (V1/2) was 20 
obtained from tail currents, normalised to the maximum tail currents measured on each 21 
individual cell during the second application of carvacrol (It/It,max). Normalised tail 22 
current-voltage relationships were then fitted to a Boltzmann equation:  23 
It
It,max
 = It,min + 
(It,max - It,min)
1 + e 
(V½ - V)
slope  
  , 24 
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where It,min and It,max are the minimum and maximum tail currents, respectively, V is the 1 
membrane voltage and slope is an inverse measure of the steepness at inflection. Tail 2 
current analysis was restricted to the voltage domain below +100 mV in order to avoid 3 
channel inactivation at strong positive potentials (see Results section, Figure 6).  4 
Modelling 5 
As an in silico model, four states and the transitions between these were modelled. To 6 
calculate the time course of channel opening or closing, the activating or deactivating 7 
component of the current traces were fitted by a mono-exponential function:  8 
y(x) = A e -x/ + C, 9 
where y(x) and C represent the current amplitude at time x and at steady-state, 10 
respectively, A is the current amplitude, and  is the time constant. To determine the 11 
time constant of the slow agonist-induced effect, the V1/2 shifts at 0 s, 10 s, 60 s, 120 s 12 
as well as 180 s and 240 s (cumulative) were considered and fitted by a double-13 
exponential function (Figure 7 C): 14 
y(x) = y
0
 + A1 e
-x/1  + A2 e
-x/2, 15 
where in addition to the above-mentioned parameters, y0 represents the current 16 
amplitude at time 0. The first exponential time constant 1 was pre-set to 3.1 s (see 17 
Results section). To reject outliers, log-transformed time constants outside of mean ± 18 
2*SD were ignored. 19 
In our model, τ1 is the time constant of the net transition rate from the closed (C) to the 20 
open (O) channel state on application of agonist, τ2 is the time constant of the reverse 21 
process, occurring on removal of the agonist. τ3 is the time constant of the transition 22 
from state 0 (unsensitised) to state 1 (sensitised) in the presence of the agonist, 23 
applicable to both closed and open channels. Based on these transition time constants, 24 
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the stochastically expected net transition was calculated for finite time periods of 0.1 s. 1 
The fraction of open channels was calculated for every state separately based on the 2 
Boltzmann equation above (It/It,max) and cumulated.  3 
Immunocytochemistry 4 
To examine trafficking of TRPA1 to the cell membrane, HEK 293t cells, transiently 5 
transfected with hTRPA1-V5, were treated with 100 µM carvacrol or with vehicle 6 
(control) in calcium-free extracellular solution for 5 min at room temperature prior to 7 
fixation. Immuncytochemistry was then performed as previously described (Btesh et al., 8 
2013). The following antibodies were used: mouse anti-V5 (1:1000; Invitrogen, Life 9 
Technologies Ltd, Paisley, UK) primary for 3 h, followed by Alexa Fluor 488 anti-mouse 10 
secondary (1:1000; Life Technologies, Paisley, UK) for 1 h. 11 
Chemicals 12 
Carvacrol, AITC, MβCD and Brefeldin A were all purchased from Sigma-Aldrich 13 
(Gillingham, UK). H89 was purchased from Cayman Chemical (Ann Arbor, USA). 14 
HC030031 was a kind gift from Dr Sarah Skerratt, Neusentis, Pfizer (Granta Park, 15 
Cambridge, UK). AITC, H89 and HC030031 were dissolved in DMSO. The final 16 
concentration of DMSO did not exceed 0.1 %. Carvacrol was diluted directly in calcium-17 
free HEPES-buffered extracellular solution and Brefeldin A was dissolved in ethanol. 18 
MβCD was dissolved in cell culture medium and cells incubated prior to the start of the 19 
experiment.  20 
Data analysis 21 
Repetitive application of TRPA1 agonists such as carvacrol caused a steady increase 22 
in response amplitude (see for example Figures 1 & 2). In order to limit the time taken 23 
for recordings, and to reduce variability which may be caused by cell deterioration in 24 
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very long experiments, we quantified fractional agonist-induced sensitisation under 1 
different conditions as the peak current induced by the sixth agonist application divided 2 
by the peak current induced by the first application.  3 
Two groups of data containing < 10 samples were compared using the nonparametric 4 
U test. Two groups of data containing ≥ 10 samples were compared using the paired or 5 
unpaired t-test as appropriate. Multiple groups were compared by one-way or repeated 6 
measures ANOVA followed by either Dunnett’s multiple comparison or Bonferroni post 7 
hoc test as appropriate. Recovery ratios in Figure 5 D were statistically compared to 8 
the value of 1 using a one-sample t-test. Statistical analysis was performed using 9 
Statistica 8 (StatSoft, Bedford, UK) or Prism 6 (GraphPad Software, Inc., La Jolla, 10 
USA). Data are presented as mean  SEM; p < 0.05 was considered significant. 11 
Significance levels are as follows: n.s., not significant; *p < 0.05; **p < 0.01; ***p < 12 
0.001.  13 
 14 
Results 15 
Repeated agonist-induced activation sensitises TRPA1 16 
Responses of TRPA1 in DRG neurons to a submaximal dose of AITC have been 17 
shown to increase with each application under calcium-free conditions (Raisinghani et 18 
al., 2011). Here, we confirmed that repeated application of the electrophilic agonist 19 
AITC (50 µM) induces increasing inward currents in adult mouse DRG neurons 20 
expressing TRPA1 (Figure 1 A, C). The non-electrophilic TRPA1 agonist carvacrol (100 21 
µM), which activates TRPA1 at a different agonist binding site (Lee et al., 2008) also 22 
induced increasing inward currents (Figure 1 B, C). Both agonists also induced a 23 
similar sensitisation in HEK293t cells expressing hTRPA1 (Figure 1 D–F).  24 
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TRPA1 can also be activated by strong depolarising voltage steps in the absence of 1 
agonist (Figure 1 G; see also Figure 6). The time-dependent activation during the 2 
pulse, and the current deactivated on return to the holding potential, are both TRPA1-3 
dependent as much smaller and time-independent currents are observed in 4 
untransfected cells (Figure 1 H). However, in contrast to the increasing current 5 
activated by repeated agonist application, we found that TRPA1 currents elicited by 6 
depolarisation were stable and did not show any sign of sensitisation, either during a 7 
train of activating pulses or when the train was repeated after 5 min (Figure 1 I). 8 
Sensitisation was also not observed with longer voltage pulses, of the same duration 9 
as the exposures to carvacrol in Figure 1 E (Figure 1 J–K).  10 
Sensitisation of TRPA1 is independent of N-terminal cysteine modification or cell 11 
signalling pathways 12 
Activation of TRPA1 by electrophilic agonists such as AITC depends on the covalent 13 
modification of three N-terminal cysteine residues, C621, C641 and C665 (Hinman et 14 
al., 2006; Macpherson et al., 2007). We mutated all three cysteine residues to serine 15 
(hTRPA1-C621S-C641S-C665S, 3C mutant), and used the non-electrophilic agonist 16 
carvacrol to activate TRPA1. Repeated application of carvacrol still potently sensitised 17 
TRPA1 (Figure 2 A, F), showing that the three cysteine residues are not required for 18 
agonist-induced sensitisation.  19 
Next, we tested if cell signalling pathways utilising intracellular ATP were responsible 20 
for sensitising TRPA1, a mechanism that is well known for the TRPV1 ion channel 21 
(Cesare & McNaughton, 1996; Tominaga et al., 2001; Vellani et al., 2001). However, 22 
removing all ATP and GTP from the intracellular solution and all glucose from the 23 
extracellular solution to prevent metabolic production of ATP did not reduce carvacrol-24 
induced sensitisation, and surprisingly sensitisation was significantly more potent 25 
compared to control experiments (Figure 2 B, F).  26 
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TRPA1 has been reported to be sensitised by inflammatory mediators via activation of 1 
intracellular protein kinase A (PKA), although this has been disputed in a later study 2 
(Wang et al., 2008a; Raisinghani et al., 2011). However, applying the PKA inhibitor 3 
H89 (10 µM) did not reduce agonist-induced sensitisation of TRPA1 (Figure 2 C, F). 4 
This concentration of H89 was chosen as it has previously shown to be effective in 5 
blocking bradykinin or forskolin-induced activation of PKA (Wang et al., 2008a; and 6 
JEM unpublished data). 7 
Migration of ion channels into lipid rafts has been reported to potentiate their activation 8 
(Liu et al., 2006; Szőke et al., 2010). Lipid rafts can be disrupted by depletion of 9 
cholesterol from the cell membrane by methyl-β-cyclodextrin (MβCD). However, 10 
incubation of hTRPA1-expressing HEK293t cells in MβCD before the recording did not 11 
influence the sensitisation induced by repeated application of carvacrol (Figure 2 D, F). 12 
We used MβCD at a similar time of application and concentration that has been shown 13 
to diminish capsaicin-induced responses in TRPV1-expressing cells (Szőke et al., 14 
2010).  15 
Finally, we observed that an initial sustained carvacrol application causes slow 16 
sensitisation, as seen in a slow increase of inward current (Figure 2 E). Once the 17 
channel has fully entered the sensitised state, little further sensitisation is seen during 18 
repetitive application of agonist (Figure 2 E, F).  19 
Trafficking of TRPA1 to the membrane is not involved in carvacrol-induced 20 
sensitisation 21 
It has previously been reported that TRPA1 ion channels can be trafficked to and 22 
inserted into the cell membrane in response to activation of the channel by AITC and it 23 
was argued that this mechanism contributes to increased sensitivity of neurons to 24 
TRPA1 agonists (Schmidt et al., 2009). We therefore investigated whether enhanced 25 
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trafficking might be responsible for agonist-induced sensitisation of TRPA1. HEK293t 1 
cells transfected with hTRPA1-V5 were exposed to carvacrol (100 µM) for 5 min in a 2 
calcium-free solution, similar to the carvacrol exposure in Figure 2 E. TRPA1 was 3 
detected using a V5 antibody, and wheat germ agglutinin (WGA) was used to define 4 
the location of the plasma membrane (Btesh et al., 2013). However, no difference was 5 
observed in the presence of TRPA1 at the cell membrane after carvacrol treatment 6 
when compared to control cells treated with vehicle (Figure 3 A–C).  7 
To extend these findings we repeated the electrophysiological recordings described 8 
above on hTRPA1-expressing HEK293t cells that had been incubated with the protein 9 
transport inhibitor Brefeldin A (5 µg/ml). Brefeldin A has been successfully used to 10 
block trafficking of other ion channels, such as P2X (Fabbretti et al., 2006; Lalo et al., 11 
2010) and TRPV1 (Johansen et al., 2006). However, blocking trafficking with brefeldin 12 
A had no effect on the sensitisation induced by repeated application of carvacrol 13 
(Figure 3 D, E).  14 
We next measured surface membrane TRPA1 expression directly by maximally 15 
activating TRPA1 with a saturating dose of 5 mM carvacrol. The large membrane 16 
currents observed with maximal activation were reduced by removing all but 10 mM 17 
extracellular Na+ in order to avoid patch clamp artefacts. Instead of the increasing 18 
inward currents that would be expected if exposure to agonist had induced trafficking of 19 
TRPA1 to the membrane, we instead observed tachyphylaxis of the induced responses 20 
(Figure 3 F, G). These results are in accordance with those obtained by another group 21 
(Raisinghani et al., 2011) and argue against increased channel insertion into the cell 22 
membrane.  23 
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Sensitisation is independent of agonist site-of-action and of ion flux 1 
Electrophilic agonists, such as AITC, activate the channel via intracellular N-terminal 2 
cysteine modification (Hinman et al., 2006; Macpherson et al., 2007), while non-3 
electrophilic agonists such menthol activate by binding to a site within transmembrane 4 
domain 5 (Xiao et al., 2008a). Carvacrol also acts at the same site as menthol, 5 
because mutating two amino acids, S873 and T874, within transmembrane domain 5 of 6 
hTRPA1 to valine and leucine, respectively, completely abolished sensitivity to 7 
carvacrol but not to AITC (Figure 4 C–E). We studied cross-sensitisation between AITC 8 
and carvacrol to investigate whether the sensitisation induced by a specific agonist is 9 
limited to activation at its own binding site. Sensitisation was induced with either AITC 10 
or carvacrol, followed by a test of sensitisation by applying a pulse of carvacrol. 11 
Channel activation by either agonist caused equivalent sensitisation (Figure 4 A), and 12 
in cells exposed to AITC, the following carvacrol response was significantly sensitised 13 
compared to control cells not exposed to AITC (Figure 4 B). Sensitisation is therefore 14 
independent of the agonist’s site of action.  15 
The S873V/T874L mutant allowed us to examine the possibility that carvacrol might 16 
cause sensitisation by binding to a site other than that at which it activates the ion 17 
channel. Application of carvacrol to the S873V/T874L mutant failed to activate the 18 
channel (Figure 4 C–E) and also failed to cause any sensitisation, as probed by a 19 
subsequent pulse of AITC (Figure 4 F). Thus both activation and sensitisation are 20 
mediated by binding of carvacrol to an activation domain containing the S873V/T874L 21 
site.  22 
We used the TRPA1 antagonist HC030031 to test if channel block could abolish 23 
carvacrol-induced sensitisation. Channel block during a series of applications of 24 
carvacrol did not affect sensitisation because responses after channel block were 25 
comparable in amplitude to recordings where no antagonist had been applied (Figure 5 26 
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A) and were significantly increased compared to responses before channel block 1 
(Figure 5 B). To investigate the time course of recovery from carvacrol-induced 2 
sensitisation, we applied carvacrol with variable gaps between each application (Figure 3 
5 C) and found no evidence for recovery over 240 s (Figure 5 D).  4 
Prolonged activation of TRPA1 by an agonist as shown in Figure 5 C (see inset) 5 
showed the existence of two distinct processes during sustained channel activation. 6 
The initial current increase reached a plateau within a few seconds, which was followed 7 
by a delayed secondary current increase with a similar time course as the onset of 8 
sensitisation.  9 
Taken together, the results described in this section show that sensitisation is driven 10 
when TRPA1 is activated by agonists but not by voltage. Sensitisation has a slow 11 
onset, reverses very slowly in the absence of agonist, and is independent of cell 12 
signalling pathways.  13 
Sensitisation is accompanied by a change in dependence of TRPA1 on 14 
membrane voltage 15 
To investigate whether sensitisation induced by carvacrol may be accompanied by 16 
changes in the intrinsic gating properties of TRPA1 we compared the voltage-17 
dependent activation of TRPA1 in unsensitised and sensitised states. Under calcium-18 
free conditions we applied carvacrol (100 µM) while testing for current activation using 19 
a rapid ramp protocol (Figure 6 A). At the indicated time points before and during 20 
carvacrol, we used a protocol of repeated voltage pulses to examine the voltage 21 
dependence of activation (Figure 6 B). Steady-state current at the end of each test 22 
pulse was used to obtain the I-V relationship (Figure 6 C, D) and the tail current at +60 23 
mV following each pulse was used to calculate the voltage dependence of channel 24 
activation (Figure 6 E).  25 
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Before application of carvacrol, voltage-dependent activation was observed only at 1 
strongly positive potentials (Figure 6 B, C; time point 1). Application of carvacrol 2 
(100 µM) induced an increase in steady-state currents at all voltages (time point 2) 3 
which gradually increased (time points 3, 4). Moreover, we observed channel 4 
inactivation at strongly depolarised voltages following prolonged application of 5 
carvacrol (time point 4). After washout of carvacrol, activation only by strongly positive 6 
membrane voltages was restored (Figure 6 D; time point 5). Surprisingly, when we 7 
measured voltage dependence again during a second carvacrol application, there was 8 
a marked negative shift in the I-V relationship between each time point and its 9 
corresponding point during the first application (compare Figure 6 C and D). Steady-10 
state current at +70 mV at the end of the second carvacrol application (time point 8) 11 
had increased by 33 % compared to the end of the first application (time point 4). Note 12 
that there is not an exact correspondence between current measured with the rapid 13 
ramp protocol in Figure 6 A, which does not allow current to reach a steady-state, and 14 
the steady-state current measured with the step protocol in Figure 6 B.  15 
We next used tail currents at +60 mV as a measure of the voltage dependence of 16 
channel activation (Figure 6 E). Corresponding to our observations above, TRPA1 was 17 
activated only at strongly depolarised membrane potentials in the absence of agonist 18 
(time point 1), which is in agreement with previous reports (Meseguer et al., 2008; 19 
Fajardo et al., 2008) although others have reported stronger activation at potentials 20 
above +100 mV (Karashima et al., 2007; Zurborg et al., 2007). With prolonged agonist 21 
application (see time points 4 and 8) tail currents were reduced following strong 22 
depolarisations, with currents reaching a maximum at +70 mV and then decreasing 23 
steadily (Figure 6 E). Voltage-dependent TRPA1 channel inactivation at strongly 24 
positive membrane potentials has been noted in previous publications (Karashima et 25 
al., 2007, 2008; Macpherson et al., 2007; Andersson et al., 2008; Fajardo et al., 2008; 26 
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Talavera et al., 2009) and the basis for this inactivation is unknown. In analysing tail 1 
currents we therefore restricted analysis to the voltage domain below +100 mV. 2 
Voltage-dependent activation of TRPA1 was quantified from tail currents normalised to 3 
the maximum tail current measured for each individual cell during either of the two 4 
responses. These tail current-voltage relationships were fitted by a Boltzmann function 5 
to calculate the voltage at which current was half-activated, V1/2 (Figure 6 E). In the 6 
absence of agonist, we measured a V1/2 of +170 ± 13 mV,  which is similar albeit 7 
slightly higher than what has been previously reported for TRPA1 (Karashima et al., 8 
2007; Zurborg et al., 2007; Kremeyer et al., 2010). During application of carvacrol, we 9 
found an initial rapid negative shift of the activation V1/2; after 10 s exposure V1/2 was 10 
+94  16 mV (time point 2; p = 0.05 when compared to time point 1; n = 11). A slow 11 
negative shift followed; after 60 s exposure, V1/2 had shifted to +34  20 mV (not 12 
shown; p < 0.001 compared to time point 1; n = 11) and after 120 s exposure, V1/2 had 13 
shifted even further to –36  24 mV (time point 4; p < 0.001 compared to time point 1; n 14 
= 11; all Repeated Measures ANOVA with Bonferroni post hoc analysis) (Figure 6 E). 15 
Corresponding to observations from steady-state I-V relationships, tail current-voltage 16 
relationships returned to baseline values between carvacrol applications (time point 5; 17 
+179 ± 14 mV; p = 0.99 compared to time point 1), indicating that the shift of the 18 
activation curve was not due to factors such as progressive dialysis of the intracellular 19 
solution. The activation curves during the second carvacrol application, which had been 20 
shown in other experiments to cause significant sensitisation, were all shifted towards 21 
more negative potentials when compared to the corresponding time points in the first 22 
carvacrol application, indicating that part of the negative shift had been conserved 23 
between applications. We measured an activation V1/2 of +22  12 mV (p = 0.08), –93 ± 24 
25 mV (p < 0.001) and –132 ± 18 mV (p = 0.003) after 10 s, 60 s and 120 s of the 25 
second application, respectively (all compared to corresponding time points in the first 26 
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carvacrol application; n = 11; Repeated Measures ANOVA with Bonferroni post hoc 1 
analysis).  2 
We next developed a model to explain the time course of sensitisation of TRPA1 3 
activation during repetitive applications of carvacrol at a single agonist concentration 4 
and at a fixed membrane potential in experiments such as that shown in Figure 1 E. 5 
First, the transition from the closed to the open channel state was compared between 6 
the first and the 20th carvacrol application (100 µM, 15 s, holding potential –60 mV), i.e. 7 
before and after agonist-induced sensitisation. The time constant of channel opening 8 
determined by a mono-exponential fit to the current traces was not significantly 9 
different between these applications (p = 0.43; paired t-test). Therefore the transition to 10 
the open state was modelled with a single constant τ1 = 3.1 ± 1.1 s in both the basal 11 
and the sensitised state. Similarly, the time constant of channel closing after agonist 12 
removal was fitted after the first and the 20th application (p = 0.16; paired t-test) and the 13 
closing time constant was determined as τ2 = 1.5 ± 0.5 s.  14 
Based on these findings, we propose a model with two open and two closed 15 
conformations, either in the unsensitised (C0–O0) or the sensitised channel state (C1–16 
O1) (Figure 7 A). Because time constants for agonist-dependent channel opening or 17 
closing are not different in the unsensitised or sensitised state (see above), we suggest 18 
that the rapid gating of TRPA1 by agonist and voltage (applicable for both C0–O0 and 19 
C1–O1) is independent of the additional slow agonist-induced effect, which can be seen 20 
in the slow shift of voltage dependence (Figure 6 E) and which is described by a 21 
transition to an additional sensitised channel closed-open state (C1–O1). We therefore 22 
suggest that sensitisation consists of a slow and progressive accumulation of channels 23 
in the sensitised state (C1-O1). Since this slow effect is agonist-dependent, we 24 
modelled this with one time constant (τ3) for both transitions C0–C1 and O0–O1. To 25 
determine the time constants of this process, the change in V1/2 at 0 s, 10 s, 60 s, 120 s 26 
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as well as 180 s and 240 s (cumulative) after exposure to carvacrol was fitted by a 1 
double-exponential with the fast time constant being equal to the time constant for 2 
transition τ1 = 3.1 s (see above) from the closed to the open state (Figure 7 C). The 3 
slow time constant 3 was taken to represent the transition from state 0 to state 1 and 4 
was determined as τ3 = 130 ± 27 s. In addition, this double-exponential fit resulted in a 5 
V1/2 shift from a baseline of +174 ± 11 mV to +99 ± 13 mV (75 mV shift) with time 6 
constant τ1 and an additional V1/2 shift to -175 ± 24 mV with time constant τ3 (274 mV 7 
shift) (see Figure 7 C).  8 
With these parameters, a repetitive carvacrol application was modelled, considering the 9 
four possible channel states, the described transitions, and the V1/2-dependent open 10 
probability of the four channel states at −60 mV using the described Boltzmann 11 
equation (Figure 7 B). The time to reach a rapid equilibrium of the open probability is 12 
an order of magnitude shorter than the slow V1/2-shift and was therefore ignored in the 13 
model. The modelled result shows a good agreement with the experimental 14 
observations (see e.g. Figure 1 E), and can therefore explain the slow current increase. 15 
At the end of the first application in the model 14% of all channels are open, while a 16 
4.7-fold increase is predicted at the end of the 12th application (black trace). Figure 7 B 17 
overlays the percentage of channels in state 1 (red trace) to demonstrate how the 18 
observed current increase can be predicted by a slow transition to this state. 19 
Because of the different values of V1/2 in state O0 and O1, the model predicts that when 20 
both states are occupied there will be a mixture of values of V1/2 and therefore a 21 
detectable decrease in the slope of conductance-voltage relationships. A minimum 22 
slope is to be expected when 50% of channels are in each state (Figure 7 D). Indeed 23 
this decrease was observed in our experiments (see Figure 6 E), the slope of the 24 
current-voltage relationship at 120 s (time point 4) was significantly lower compared to 25 
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time points 2 and 8 (p < 0.001 and p = 0.002, respectively; Repeated Measures 1 
ANOVA with Bonferroni post hoc analysis; n = 11).  2 
Discussion 3 
We have shown that repeated activation of the irritant receptor TRPA1 by agonists, but 4 
not by membrane voltage, leads to a pronounced sensitisation of TRPA1 under 5 
calcium-free conditions. This agonist-induced sensitisation could be observed both in 6 
HEK293t cells expressing hTRPA1 and in adult mouse DRG neurons. Sensitisation is 7 
not limited to a specific class of agonist, as it is seen both with AITC and with carvacrol, 8 
which activate TRPA1 at different binding sites and by different mechanisms. In 9 
addition, the presence of intracellular ATP and the formation of lipid rafts, which are 10 
known to modulate TRPV1 (Tominaga et al., 2001; Liu et al., 2006; Szőke et al., 2010), 11 
as well as activation of PKA, which has been shown to enhance activation of TRPA1 12 
(Wang et al., 2008a), are not involved in agonist-induced sensitisation of TRPA1. A 13 
further possibility is that exposure to agonists may increase trafficking and insertion of 14 
TRPA1 channels into the cell membrane, as has been proposed for sensitisation by 15 
AITC (Schmidt et al., 2009). In the present study, however, we were not able to find 16 
any support for enhanced trafficking as an explanation for the sensitisation induced by 17 
agonists of TRPA1. It should be noted that AITC-induced trafficking of TRPA1, reported 18 
by Schmidt et al. (2009), was calcium-dependent and did not occur in a calcium-free 19 
environment, while the sensitisation reported in the present study was observed in the 20 
absence of extracellular calcium and is therefore likely to be a different phenomenon. 21 
Blocking intracellular protein transport with Brefeldin A, which blocks trafficking of P2X 22 
and TRP channels (Johansen et al., 2006; Fabbretti et al., 2006; Lalo et al., 2010; Ma 23 
et al., 2010), did not reduce sensitisation caused by carvacrol. Furthermore, we did not 24 
see an enhancement in maximal current activated by a saturating dose of agonist, as 25 
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would be expected if sensitisation was due to an increase in surface expression of 1 
TRPA1, and in fact observed tachyphylaxis of maximal responses.  2 
Sensitisation is independent of the agonist’s site of action, because channel activation 3 
by AITC sensitised responses to carvacrol, even though the two agonists activate 4 
TRPA1 at distinct sites. Furthermore, sensitisation is independent of ion flux as it 5 
occurs during channel block by HC030031. Current traces during prolonged activation 6 
showed a pattern of two distinct phases, with a secondary increase in inward current 7 
that has a surprisingly slow time constant that exceeds by far the time constant of 8 
channel activation and even of pore dilation (Chen et al., 2009; Meseguer et al., 2014). 9 
In the absence of evidence for other possible mechanisms, we hypothesised that the 10 
agonist-induced sensitisation of TRPA1 may depend on changes in the intrinsic gating 11 
properties of the channel. A similar pattern was found in the TRPV3 ion channel, which 12 
is also sensitised by repeated activation by heat and by agonists (Chung et al., 2005; 13 
Xu et al., 2006; Liu et al., 2011). Voltage-dependent gating of TRPA1 depends on a 14 
number of factors including the presence or absence of external calcium, the cell type 15 
and whether human or rodent TRPA1 is studied. Most studies used mouse TRPA1, 16 
expressed in Chinese hamster ovary cells (Karashima et al., 2007, 2009; Macpherson 17 
et al., 2007; Meseguer et al., 2008; Andersson et al., 2008; Fajardo et al., 2008; 18 
Talavera et al., 2009), before major species differences were discovered (Xiao et al., 19 
2008a). In the present study we used the human isoform, transiently transfected into 20 
HEK293t cells.  21 
 22 
Synergy between activation of TRPA1 by agonists and by membrane voltage 23 
TRPA1 was found to be activated by strong depolarisation even in the absence of 24 
agonist, and carvacrol caused a shift of the voltage dependence of channel gating to 25 
more negative membrane potentials, as has been reported for other TRPA1 agonists 26 
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and for cold temperatures (Karashima et al., 2007, 2009; Zurborg et al., 2007; 1 
Meseguer et al., 2008; Fajardo et al., 2008; Talavera et al., 2009). Here, we measured 2 
a V1/2 of +170 mV under agonist-free conditions. The voltage-sensitivity of TRPA1 3 
activation was very weak, with a mean value for the slope factor of 54.9 mV (Figure 6 4 
E). This corresponds to a gating charge movement of z = 0.46 for all four subunits 5 
across the full electric field, or z = 0.12 per subunit. The value of z obtained here is 6 
similar to that previously reported (0.375, Karashima et al., 2009) and corresponds to 7 
movement of a single charge per subunit across only a small fraction (12 %) of the 8 
membrane field. 9 
The V1/2 was rapidly shifted in the negative direction by agonist, to +94 mV following 10 
10s application of carvacrol, and then became more negative with a slow time-course, 11 
consistent with the slow development of sensitisation, reaching a value of −36 mV after 12 
120 s exposure to carvacrol. The shift is rapidly and completely reversed on removal of 13 
agonist, but sensitisation can be seen to be conserved even if agonist is removed for 14 
times exceeding 240 s (Figure 5 C, D), a property that is shared by the negative shift of 15 
V1/2, because both current and the shift in V1/2 are seen to be enhanced following a 16 
second application of agonist (Figure 6 E).  17 
In contrast to other voltage-dependent TRP channels, TRPA1 is inactivated by strong 18 
depolarisation (see Figure 6). A similar inactivation has been reported by some studies 19 
(Karashima et al., 2007, 2008; Macpherson et al., 2007; Andersson et al., 2008; 20 
Fajardo et al., 2008; Talavera et al., 2009) but not by others (Doerner et al., 2007b; 21 
Meseguer et al., 2008; Banke et al., 2010; Wan et al., 2013). It has been proposed that 22 
this discrepancy is due to differing factors in recording conditions that negatively shift 23 
the V1/2 for inactivation to varying degrees (Wan et al., 2013). Our results clearly 24 
identify inactivation of TRPA1, both in steady-state I-V relations (Figure 6 C, D) and in 25 
tail currents (Figure 6 E), and show that channel inactivation is enhanced by prolonged 26 
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agonist exposure (Figure 6 C, D).  In the absence of a clear explanation for TRPA1 1 
inactivation at strongly positive voltages we restricted analysis of activation curves to 2 
membrane voltages below +100 mV, where inactivation is minimal. 3 
A model for sensitisation of TRPA1 4 
How is agonist-induced sensitisation caused? One possible explanation could be relief 5 
of voltage-dependent pore block by calcium, as has been reported for TRPV3 (Chung 6 
et al., 2005; Xiao et al., 2008b), although a more recent study has shown that a 7 
component of sensitisation of TRPV3 is calcium-independent and therefore resembles 8 
the sensitisation studied in the present paper (Liu et al., 2011). Another possibility is a 9 
time-dependent increase in pore diameter, which is enhanced under calcium-free 10 
conditions (Chen et al., 2009; Banke et al., 2010; Karashima et al., 2010; Bobkov et al., 11 
2011). However, pore dilation occurs within less than 15 s of AITC application and well 12 
before maximal channel activation (Chen et al., 2009; Banke et al., 2010), which 13 
challenges the contribution of pore dilation for the long-lasting agonist-induced 14 
sensitisation that was shown here. A further possibility is that agonists may induce a 15 
transformation of the channel conformation leading to enhanced sensitivity to 16 
membrane voltage and therefore to sensitisation. We propose a model for TRPA1 17 
sensitisation (Figure 7 A) in which the channel is not only reversibly gated by agonists 18 
but also, with a time constant of more than one minute, enters a sensitised 19 
conformational state ‘1’ that allows enhanced gating. This conformational change is 20 
likely to involve a slow shift in charge distribution within the TRPA1 molecule such that 21 
the gating charge responsible for voltage-dependent channel activation is activated at 22 
progressively more negative membrane potentials (Figure 6 E). Finally, with prolonged 23 
agonist application, more and more channels accumulate in this sensitised state ‘1’, 24 
explaining the observed slow shift in voltage dependence and the accompanying 25 
change in slope factor as well as the increased inward current (Figure 7 D).  26 
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Modelling of repetitive agonist application using experimentally determined parameters 1 
resembles our experimental observations. Even if the underlying biology is more 2 
complex, a simple model with four states and three transition time constants is 3 
sufficient to produce the major features of the slow current increase in response to 4 
agonist (Figure 7 B–D) and the shift in V1/2 (Figure 7 D).  5 
Alternative models which could generate a slow current increase have been 6 
considered, e.g. as described for TRPV3 where this was termed ‘hysteresis’ (Liu et al., 7 
2011). Adopting that model, two sequential closed states before transition to one open 8 
state could generate hysteresis in case of a longer time constant between the two 9 
closed states compared to the transition to the open state. In such a scenario only the 10 
slowly rising amount of channels which can open would explain the hysteresis, and the 11 
observed V1/2 shift would not be reflected. Alternatively, one closed and two sequential 12 
open states could also generate hysteresis, but a different kinetic upon agonist removal 13 
should be expected in this case. Finally, if in our model the transition C1–O1 was at 14 
least an order of magnitude faster than C0–O0, hysteresis could also occur, but this was 15 
excluded by our observations that activation and deactivation time constants are similar 16 
in the basal and sensitised states (see Results section).  17 
Finally, we note that while activation of TRP channels by agonists or by voltage were 18 
initially thought to be equivalent (Voets et al., 2004), a more recent study has 19 
demonstrated that these two modes of activation in fact not equivalent (Matta & Ahern, 20 
2007). In the case of TRPV1 and TRPM8, membrane voltage acts only as a partial 21 
agonist, in that the increase in channel open probability caused by voltage is much 22 
smaller than the increase in open probability caused by thermal activation, and at high 23 
agonist concentrations gating is voltage-independent. 24 
Physiological relevance of sensitisation of TRPA1 25 
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Considering the physiological relevance of agonist-induced sensitisation of TRPA1, it is 1 
likely that it would initially be masked by calcium-mediated inhibition of the channel. 2 
However, the sensitising effect of agonists increases over time and sensitisation may 3 
eventually overcome the inhibition of the channel by calcium, leading in total to a 4 
sensitised channel state. Agonist-induced sensitisation could provide a mechanism for 5 
the detection of repeated or long-term exposure to harmful irritants. Such a mechanism 6 
would be especially appealing in the airways, as many TRPA1 agonists can be 7 
ingested or inhaled and the channel is implicated in the development of inflammatory 8 
airway diseases (Andrè et al., 2008; Birrell et al., 2009). This hypothesis is supported 9 
by recent findings of Kunkler et al. (2015) showing that long-term inhalation exposure 10 
of rats to sub-activating doses of the TRPA1 agonist acrolein led to increased 11 
meningeal blood flow in response to acute nasal challenge with mustard oil. Animals 12 
had been pre-exposed to acrolein four hours per day for four days, which agrees with 13 
our findings that agonist-induced sensitisation of TRPA1 is very long-lasting and 14 
potentially irreversible. This mechanism of TRPA1 sensitisation may therefore 15 
represent an important physiological function.  16 
In summary, we have shown that prolonged agonist application sensitises the TRPA1 17 
channel both in nociceptive neurons and when heterologously expressed and that this 18 
slow process is agonist-driven and is intrinsic to the channel itself. Sensitisation is 19 
accompanied by a slowly developing shift of voltage-dependent activation towards 20 
more negative membrane potentials and thus represents a slow gain-of-function. 21 
Agonist-induced sensitisation of TRPA1 may provide a mechanism for the detection of 22 
long-term exposure to harmful stimuli, which would be especially valuable in the 23 
airways, where many irritants activate TRPA1.  24 
  25 
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Figure 1 Repeated activation of TRPA1 by agonists, but not by voltage, 1 
sensitises the channel in the absence of extracellular calcium. (A) Representative 2 
whole-cell voltage-clamp recording of a DRG neuron (holding potential –60 mV) 3 
showing that repeated application of AITC (50 µM; 40 s; 90 s gap) induces increasing 4 
inward currents in 0 [Ca2+]o. (B) Repeated application of carvacrol (100 µM; 30 s; 60 s 5 
gap) to a DRG neuron also has a sensitising effect. The TRPA1-specific agonist AITC 6 
(50 µM; 40 s) was applied once at the end of the protocol. (C) Quantification of all 7 
experiments as in (A) and (B). Graph (left) shows peak current of each response, 8 
measured as current increase on application of agonist, and normalised to first 9 
response. Bar chart (right) shows fractional sensitisation measured at sixth response. 10 
AITC induced an 8.3 ± 2.5 fold sensitisation (p < 0.001 compared to first response; n = 11 
9); carvacrol induced a 1.9 ± 0.3 fold sensitisation (p = 0.01 compared to first response; 12 
n = 9). # compared to first response. * compared to carvacrol. (D–F) Similar recordings 13 
with HEK293t cells expressing hTRPA1 (holding potential –60 mV). Repeated 14 
application of AITC (50 µM; 15 s; 120 s gap) induced a 6.3 ± 1.5 fold sensitisation (p < 15 
0.001 compared to first response; n = 8) at the sixth response; carvacrol (100 µM; 15 s; 16 
30 s gap) induced a 2.1 ± 0.2 fold sensitisation (p < 0.001 compared to first response; 17 
n = 22). (G) Activation of TRPA1 by strong depolarisation has no sensitising effect. 15 18 
voltage steps from −60 mV to +160 mV, duration 1 s, applied every 7 s. Same protocol 19 
repeated after a period of 5 min. Mean current 1624 ± 98 pA (67 ± 4 pA/pF, n = 10) (H) 20 
Same protocol applied to untransfected HEK293t cells elicited much smaller 21 
background current. Scale bars as in (G). Mean current 616 ± 41 pA (32 ± 3 pA/pF; p < 22 
0.001; n = 10) (I) Peak currents, normalised to the first response of the first protocol, do 23 
not increase with repeated activation of TRPA1 (circles), and there is no significant 24 
increase during the second protocol (squares) (all p ≥ 0.34; n = 8–10). (J) Voltage 25 
protocol similar to that used for agonist application. Voltage steps from  −60 mV to 26 
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+100 mV, duration 15 s (bottom trace) applied with 30 s intervals between steps. Time 1 
point for measurement of steady-state (Iss) currents is indicated by arrow. Scale bars 50 2 
pA and 10 s. (K) Steady-state currents (Iss), normalised to the first response. No 3 
significant increase in current amplitude (all p ≥ 0.68; n = 6–8). 4 
 5 
Figure 2 Agonist-induced sensitisation does not rely on cysteine modification, 6 
ATP-signalling, phosphorylation or the formation of lipid rafts. Whole-cell voltage-7 
clamp experiments in HEK293t cells transiently transfected with hTRPA1. (A) Mutating 8 
the three intracellular cysteine residues modified by electrophilic agonists (C621, C641 9 
and C665) to serine (3C mutant) does not reduce the sensitisation induced by repeated 10 
application of carvacrol (200 µM; 15 s). (B) Complete removal of ATP potentiated 11 
sensitisation induced by carvacrol (100 µM; 15 s). Recordings were performed using 12 
ATP- and GTP-free intracellular solution and glucose-free extracellular solution. (C) 13 
Inhibiting intracellular protein kinase A (PKA) does not reduce the effect of carvacrol 14 
(100 µM; 15 s). The PKA inhibitor H89 (10 µM) was applied extracellularly throughout 15 
the recording. (D) Disruption of lipid rafts by methyl-β-cyclodextrin (MβCD, 5 mM for 15 16 
min before recording) does not inhibit sensitisation induced by carvacrol. (E) An initial 17 
sustained carvacrol application (100 µM; 150 s) before switching to repetitive 18 
application stabilises the following repetitive responses. (F) Summary graph of 19 
fractional sensitisation measured at sixth response in all experiments as in (A – F). The 20 
control group is the same as in Figure 1 (E, F). In the 3C mutant, currents had 21 
increased 2.7 ± 0.4 fold (p < 0.001 compared to first response; n = 14). In ATP-free 22 
recordings, the increase was 4.0 ± 0.7 fold (p < 0.001 compared to first response; n = 23 
4). In the presence of H89, current increase was 2.4 ± 0.2 fold (p < 0.001 compared to 24 
first response; n = 8). In the presence of MβCD, currents had increased 2.2 ± 0.3 fold 25 
(p < 0.001 compared to first response; n = 8). With the initial sustained carvacrol 26 
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application, currents had not increased at sixth response (1.0 ± 0.1 fold; n = 14). # 1 
compared to first response. * compared to control. 2 
 3 
Figure 3 Sensitisation of TRPA1 by carvacrol is not caused by increased 4 
trafficking to the membrane. (A) Images show HEK293t cells transiently transfected 5 
with WT hTRPA1-V5. Scale bar 5 µm is the same for both images. Membrane staining 6 
by WGA (bottom) was used to create a juxtamembrane ROI that was superimposed on 7 
the image of TRPA1 fluorescence (top) to measure TRPA1 levels at the membrane. A 8 
separate ROI obtained from the fluorescence within the cell defined the cytoplasm 9 
excluding the nucleus. (B) Cells were either untreated (control; top row) or stimulated 10 
with carvacrol (100 µM; 5 min; bottom row) before fixation. Scale bar (5 µm) is the 11 
same for all images. (C) Ratio of TRPA1 expression at the membrane compared to the 12 
cytoplasm was not different between control cells and those stimulated with carvacrol 13 
(p = 0.336; n = 7–8). (D, E) TRPA1-expressing HEK293t cells were incubated with 14 
Brefeldin A (BFA, 5 µg/ml) for 2–3 hours (example trace) or 5–7 hours to abolish 15 
protein trafficking to the membrane prior to start of voltage-clamp experiments. 16 
Repetitive stimulation with carvacrol (100 µM; 15 s; 30 s gap) still induces pronounced 17 
sensitisation of inward currents. After 2–3 hours BFA, sensitisation at sixth response 18 
was 2.6 ± 0.4 fold (p = 0.08) and seventh response was increased significantly (2.9 ± 19 
0.4; p = 0.015; both n = 7). After 5–7 hours, sensitisation at sixth response was already 20 
significant (2.5 ± 0.6 fold; p = 0.005; n = 6) (F, G) Repeated application of a saturating 21 
dose of carvacrol (5 mM; 6 s; 84 s gap) induces maximal currents that display 22 
tachyphylaxis. Third response is significantly smaller than the first (p = 0.034; n = 8). 23 
n.s. not significant. # compared to first response. * compared to 6th response in 100 M 24 
carvacrol. 25 
 26 
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Figure 4 Different agonists cross-sensitise. (A) Representative voltage-clamp 1 
recordings in hTRPA1-expressing HEK293t cells, showing cross-sensitisation between 2 
AITC and carvacrol. Top: sensitisation of inward currents induced by carvacrol (100 3 
µM; 15 s; 30 s gap). Bottom: recording in identical conditions but TRPA1 activated with 4 
AITC (50 µM; 150 s) before application of carvacrol. (B) Cross-sensitisation of 5 
response to carvacrol by AITC. First carvacrol-induced response is significantly larger 6 
following exposure to AITC (p = 0.016; n = 8 for AITC group, n = 24 for control). (C) 7 
Mutation S873V/T874L abolishes responses to carvacrol but not AITC. Representative 8 
recording (see Figure 1 for protocol) in HEK293t cells expressing the hTRPA1-9 
S873V/T874L mutant. No response to carvacrol was observed. AITC 100 µM was 10 
applied at the end of the protocol and response was of normal amplitude. (D) 11 
Quantification of (C), plotting the average inward current for each agonist application (n 12 
= 9). (E) Ratiometric calcium imaging confirms deletion of carvacrol response in 13 
hTRPA1-S873V/T874L mutant. Experiments performed on HEK293t cells expressing 14 
either WT hTRPA1 (black) or hTRPA1-S873V/T874L mutant (grey). Ratio of fura-2 15 
fluorescence excited at 340 nm and 380 nm plotted on vertical axis. Cells were 16 
exposed to carvacrol (12.5 µM) and AITC (50 µM) for 30 s each, followed by a 20 s 17 
application of ionomycin (5 µM) to induce a maximum response for comparison. Traces 18 
are averages of 30 (WT) and 167 (mutant) cells, SEM is represented by vertical lines. 19 
(F) Carvacrol does not cause sensitisation of responses to AITC in the S873V/T874L 20 
mutant. Responses of hTRPA1-S873V/T874L mutant (white bar; n = 3) to 50 µM AITC 21 
following 12 applications of 100 µM carvacrol were of similar magnitude to naïve 22 
responses to 50 µM AITC in WT channels (black bar; n = 9; p = 0,99). In contrast, WT 23 
channels that had been sensitised by repeated application of AITC (grey bar; n = 8) 24 
displayed significantly larger responses (p = 0,015 compared to white, p < 0,001 25 
compared to black; one-way ANOVA with Bonferroni post hoc analysis). Values for the 26 
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unsensitised and sensitised WT channels are the same as in Figure 1 D & F, 1st and 8th 1 
response, respectively.  # compared to S873V/T874L. * compared to WT unsensitised. 2 
 3 
Figure 5 Agonist-induced sensitisation of TRPA1 is independent of ion flux 4 
through the channel and is long-lasting. (A) Sensitisation of TRPA1 in HEK293t 5 
cells increases with agonist exposure even when the channel is blocked. Responses 6 
5–8 to carvacrol (100 µM; 15 s) were blocked by the specific TRPA1 antagonist 7 
HC030031 (50 µM; 155 s) (see inset) and the measured inward currents (filled 8 
squares) are compared to control recordings without antagonist (open triangles). 9 
Responses 9–12 were comparable in amplitude to recordings where no antagonist had 10 
been applied (p ≥ 0.458; n = 7 for HC030031-treated, n = 21 for control). (B) TRPA1 is 11 
significantly sensitised by agonist exposure during channel block (p < 0.001; n = 7). (C) 12 
TRPA1 sensitisation in HEK293t cells is long-lasting. Gap periods of 30 s, 120 s or 240 13 
s (dotted lines) were left between applications of carvacrol (100 µM; 120 s; solid line). 14 
Sensitisation does not recover even with 240 s rest period. Sequence of gaps was 15 
changed at random between each cell. Arrows indicate time points for calculating the 16 
recovery ratio displayed in (D). Inset: prolonged stimulation with carvacrol (100 µM; 150 17 
s) induces two phases of current increase (average ± SEM trace; n = 16). (D) The 18 
recovery ratio was calculated by measuring the early current at the end of the first 19 
steep increase (Iearly) of each response and comparing it to the peak current (Ipeak) of 20 
the previous response. None of the calculated recovery ratios were significantly 21 
different from 1 (p ≥ 0.24; n = 7–8).  22 
 23 
Figure 6 Effect of repeated carvacrol application on the voltage dependence of 24 
TRPA1. (A) Representative time course of whole-cell currents elicited by two 25 
consecutive 120 s applications of 100 µM carvacrol, measured in hTRPA1-expressing 26 
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HEK293t cells at −80 mV (bottom trace) and +80 mV (top trace). Dotted line represents 1 
zero current level. At the coloured time points labelled 1–8, voltage dependence was 2 
tested using the step-pulse protocol illustrated in (B). (B) Currents recorded at the 3 
designated time points in (A) using the indicated step-pulse protocol of 80 ms voltage 4 
steps from a holding potential of −60 mV ranging from −140 mV to +220 mV in 30 mV 5 
increments, followed by a final step to +60 mV. Time points for the measurement of 6 
steady-state (Iss) and tail (It) currents are indicated by arrows. (C) I-V relationships 7 
obtained at the end (Iss) of the voltage steps illustrated in (B). Shown are average I-V 8 
curves for time points 1–4 during the first carvacrol application. (D) I-V relationships for 9 
time points 5–8 during the second carvacrol application. (E) Normalised tail currents 10 
measured at +60 mV at the indicated time points. Curve fitting was restricted to the 11 
voltage domain below +100 mV in order to avoid channel inactivation at strongly 12 
depolarised membrane potentials (see main text). Data points that were not included in 13 
the fit are shown as open symbols. Solid lines are best fits to Boltzmann functions (n = 14 
11 cells). The following V1/2 values and slope factors (in brackets) were obtained for the 15 
given time points: time point 1, +170 mV (54 mV); time point 2, +94 mV (75 mV); time 16 
point 4, –36 mV (114 mV); time point 5, +179 mV (57 mV), time point 6, +22 mV (95 17 
mV); time point 8, -132 mV (84 mV).  18 
 19 
Figure 7 Model of agonist-induced sensitisation of TRPA1. (A) Hypothetical model 20 
containing two open (O0, O1) and two closed (C0, C1) channel states. The gating of 21 
TRPA1 by agonist and voltage is displayed in the horizontal direction and is controlled 22 
by the opening and closing time constants 1 and 2 which depend on both membrane 23 
voltage and agonist concentration. The slow agonist-induced sensitisation (vertical 24 
direction, 3) is independent of channel gating and drives the transition from C0/O0 to 25 
the sensitised state C1/O1, leading to a slow and progressive accumulation of channels 26 
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in the sensitised state (C1/O1). This accumulation means that the fraction of open 1 
channels at resting membrane potential is very different in the unsensitised and the 2 
sensitised states and this underlies the shift in the voltage dependence of channel 3 
activation shown in Figure 6 E. Experimentally, the agonist-dependent channel 4 
activation and deactivation rate was similar in both the unsensitised and the sensitised 5 
states (see main text), so the same values of 1 and 2 were used to describe agonist-6 
dependent activation and deactivation in the unsensitised and the sensitised states and 7 
at the resting membrane voltage. Agonist-induced sensitisation is long-lasting and no 8 
reversal was observed (dotted arrows). Upon washout of agonist channels rapidly 9 
close by reverting from O0 to C0 and from O1 to C1. The thickness of arrows reflects the 10 
transition rates of the respective process at physiological membrane potentials in the 11 
absence of agonist. (B) Based on the model shown in (A), the expected inward 12 
currents upon repetitive carvacrol stimulation were simulated. In the model an 13 
increasing current (black line, left axis) is generated by the agonist-dependent 14 
transition from state 0 into the sensitised state 1. The fraction of channels in the 15 
sensitised state 1 is shown by the red line (right axis). The overall increase in current in 16 
the model matches the experimental observation (see for example Figure 1 E). Note 17 
that in voltage-clamp recordings, the current reaches a plateau or briefly decreases 18 
within 15 s (see Figure 5 C inset), reflecting a desensitising component which is 19 
omitted in the model for simplicity. (C) Average V1/2 values of channel opening 20 
measured as shown in Figure 6 E were fitted by a double-exponential function (red 21 
line) to derive a time constant τ3 for the slow agonist-induced sensitisation. The value of 22 
τ1 = 3.1 s, the measured time constant of current activation following agonist 23 
application (see Results section), provided a reasonable fit to the rapid phase of 24 
negative shift of V1/2. The slow V1/2 shift had a time constant of 3 = 130 ± 27 s (n = 11 25 
cells). (D) We simulated the voltage-dependent open probability of TRPA1 according to 26 
  42 
the four-state model in (A). Following carvacrol application, the voltage-dependent 1 
open probability shows a transition from C0 to O0 with a time constant of 3.1 s (see 2 
above and Results section). As a result the current at −60 mV increases from 0.014 to 3 
0.053 of the maximal current. Additional lines reflect the slow transition from O0 to O1. 4 
This transition, with a time constant of 130 s (see C), increases the current at −60 mV 5 
from 0.053 to 0.892 of the maximum. Note that the mixture of two states O0 and O1 6 
means that the slope of the curve is decreased during the transition period, as was 7 
seen in Figure 6 E.  8 
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